The new project would see 288 apartments and 19,000 square feet of commercial space built on the corner of Bull Street and ...
Progressive (NYSE:PGR – Free Report) had its price objective boosted by UBS Group from $275.00 to $285.00 in a report issued ...
Commercial property owner Sheldon Jackson has become perhaps the loudest anti-progressive voice in Spokane, rallying a following almost entirely by email.
When a woman walking to work at River Park Square this winter was dragged into an alley behind P.F. Chang's and mugged, Spokane developer and commercial property owner Sheldon Jackson and like-minded ...
18h
Zacks Investment Research on MSNIf You Invested $1000 in Progressive a Decade Ago, This is How Much It'd Be Worth NowHow much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...
We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...
When Newsom vetoed state Sen. Scott Wiener ’s marquee SB 1047 on AI safety last year, he announced a three-member panel to ...
With Canada’s economy and even sovereignty under unprecedented threat from its southern neighbour the United States, its new leader has embarked on a trans-Atlantic trip to strengthen ties with ...
Foresight Canada is excited to partner with Amlamgog (Fort Folly First Nation) to launch the Amlamgog Community Microgrid Challenge, inviting innovators to present scalable, renewable energy ...
3d
Zacks Investment Research on MSNCommercial Lines Business Aids Selective Insurance, Cat Loss AilsSelective Insurance Group Inc. SIGI is set to grow on rising premiums aided by solid renewal pure pricing, high retention and new business growth in Commercial Lines and Excess and Supply Lines. SIGI ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...
Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results